ARS Pharmaceuticals cuts 2026 expenses after no new neffy coverage gains
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
ARS Pharmaceuticals Provides Commercial and Financial Updates
June 24, 2026 4:05 PM EDTNo new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion
Total 2026 cash-based operating expenses, excluding COGS, lowered to $248 million, reflecting lower second-half spending and continued investment discipline
Company reaffirms neffy base business supports a path to cash-flow breakeven in 2027
Phase 2b chronic spontaneous urticaria (CSU) program interim data readout expected Q4 2026
SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals,... More
